Staccato Loxapine Pulmonary Safety in Patients With COPD

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The purpose of this study is to assess the pulmonary safety of 2 doses of Staccato Loxapine within a day in patients with COPD.

Key facts

Study ID

NCT00889837

Run by

Alexza Pharmaceuticals, Inc.

People needed

53

Starts

2009-06-01

Expected to finish

2009-08-01

Last updated by the study team

2017-03-14

Who can join

Age: 40 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• History of COPD for at least 6 months with pre-bronchodilator FEV1 ≥40% of predicted value and >15 pack-year history of cigarette smoking.

You may not qualify if…

• History of asthma, or any other acute or chronic pulmonary disease.

Where it is running

• Spartanburg Medical Research — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.